$109 Million is the total value of BML Capital Management, LLC's 26 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -23,749 | -100.0% | -0.02% | – |
Exit | INVIVYD INC | $0 | – | -134,696 | -100.0% | -0.13% | – | |
Exit | MEI PHARMA INC | $0 | – | -22,966 | -100.0% | -0.14% | – | |
GRPH | Exit | GRAPHITE BIO INC | $0 | – | -152,291 | -100.0% | -0.36% | – |
TLYS | Exit | TILLYS INCcl a | $0 | – | -190,518 | -100.0% | -1.20% | – |
CRTX | Exit | QUINCE THERAPEUTICS INC | $0 | – | -1,411,839 | -100.0% | -1.91% | – |
ANF | Exit | ABERCROMBIE & FITCH COcl a | $0 | – | -117,500 | -100.0% | -3.98% | – |
Exit | PARDES BIOSCIENCES INC | $0 | – | -3,791,633 | -100.0% | -6.17% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-10-23
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
SPDR SER TR | 4 | Q3 2023 | 16.9% |
ADVERUM BIOTECHNOLOGIES INC | 4 | Q3 2023 | 7.4% |
ELIEM THERAPEUTICS INC | 4 | Q3 2023 | 6.4% |
ATHIRA PHARMA INC | 4 | Q3 2023 | 4.9% |
ASTROTECH CORP | 4 | Q3 2023 | 2.8% |
ARCA BIOPHARMA INC | 4 | Q3 2023 | 1.9% |
FORTE BIOSCIENCES INC | 4 | Q3 2023 | 1.6% |
VERRICA PHARMACEUTICALS INC | 4 | Q3 2023 | 2.9% |
PASSAGE BIO INC | 4 | Q3 2023 | 1.7% |
RETRACTABLE TECHNOLOGIES INC | 4 | Q3 2023 | 1.0% |
View BML Capital Management, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR/A | 2024-04-24 |
13F-HR | 2024-04-23 |
13F-HR/A | 2024-02-02 |
13F-HR | 2024-01-30 |
13F-HR | 2023-10-23 |
13F-HR | 2023-07-24 |
13F-HR | 2023-04-14 |
13F-HR | 2023-02-13 |
View BML Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.